Pharmacology
Support for Bezafibrate
Fed Pract. 2009 July;26(7):E3
Bezafibrate, used widely in the United Kingdom to treat dyslipidemia, has not been approved for use in the United States. But that may change: Researchers from the University of Pennsylvania, Philadelphia and Centocor Research and Development, Malvern, PA say they have found strong evidence that bezafibrate can prevent or delay the onset of type 2 diabetes—an effect “unique” among the fibrate medications.